NewMed Energy - Limited Partnership (NWMD) Fair Value & Analysis

Energy · Il · Market cap 19.3B ILA · ISIN IL0004750209

What is NewMed Energy - Limited Partnership really worth?

NE NewMed Energy - Limited Partnership NWMD · TA

Price17.19 ILA

Fair Value10.77 ILA

Upside−37.4%

Quality57/100

A solid business, but trading 60% above our fair value of 10.77 ILA.

Watch NewMed Energy - Limited Partnership for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Highly profitable · 29.8% net margin

✓Moderate debt · generates free cash flow

Risks

!Weak Growth (revenue 5y +9.8 %/yr)

!Trails peers (4/14)

!Moderate moat 54/100

!Weak on dividend: 25 out of 100

Evidence: High Range 6.94 ILA – 17.19 ILA

Fair value as of: Aug 20, 2026

From 26 valuation models · updated 16 days ago

Fair value updated Aug 20, 2026, revised from 3.03 ILA to 10.77 ILA (+255.4%) since Aug 13, 2026. Share price +2.7% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
A fairly wide model range (6.94 ILA to 17.19 ILA) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 20, 2026.

How to read this chart

60‑month range 3.33 ILA – 21.97 ILA · fair‑value band 6.94 ILA – 17.19 ILA · the 17.19 ILA price screens above the 10.77 ILA fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 20, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

NewMed Energy - Limited Partnership (NWMD) currently trades at 17.19 ILA, while our model-based Fair Value estimate is 10.77 ILA, implying the stock looks roughly 59.6% overvalued today. The Quality Score stands at 57/100 (solid quality), in the Energy sector. Bull case: the Growth Earnings group reads highest at a median of 6.65 ILA per share, and 0 of the 25 models we run sit above the 17.19 ILA price. Bear case: the Asset-Based group reads lowest at 1.08 ILA, and 25 of the 25 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, NewMed Energy - Limited Partnership generated revenue of 762M ILA at a net margin of 29.8%. Revenue declined 42.6% year over year. It earns a return on equity of 13.2%. Net debt stands at 1.0B ILA. Fundamentals as of Aug 20, 2026

Our scenario range runs from 6.94 ILA (bear case) to 17.19 ILA (bull case); at 17.19 ILA, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Energy peers we cover trades at −35% fair-value upside, at −37%, NWMD screens richer than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly 0.2619 ILS per share, which is 2.4 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence

Highest evidence

EPV 2.43 ILA 3.02 ILA 3.53 ILA 74

FCF DCF 2.72 ILA 5.78 ILA 13.76 ILA 73

Growth DCF 2.59 ILA 6.55 ILA 13.07 ILA 73

All 26 models by family

DCF Models

FCF DCF 2.72 ILA 5.78 ILA 13.76 ILA 73

Owner Earnings 2.96 ILA 7.45 ILA 16.31 ILA 70

5Y Revenue Exit 0.5200 ILA 1.41 ILA 2.61 ILA 68

5Y EBITDA Exit 2.00 ILA 4.77 ILA 8.51 ILA 71

5Y P/E Exit 2.28 ILA 5.41 ILA 9.27 ILA 67

10Y Revenue Exit 1.15 ILA 2.35 ILA 4.03 ILA 64

10Y EBITDA Exit 2.21 ILA 4.96 ILA 9.59 ILA 64

10Y P/E Exit 2.40 ILA 5.44 ILA 10.30 ILA 60

Earnings-Based

Graham-Dodd 2.15 ILA 13.32 ILA 18.59 ILA 63

Lynch FV 3.83 ILA 5.47 ILA 7.11 ILA 61

PEG = 1.0 3.83 ILA 5.47 ILA 7.11 ILA 57

EPV 2.43 ILA 3.02 ILA 3.53 ILA 74

Dividend Discount

Gordon GGM 2.03 ILA 4.23 ILA 6.71 ILA 66

DDM Multi-Stage 2.03 ILA 3.57 ILA 4.44 ILA 66

Multiples

P/E Multiple 3.32 ILA 4.43 ILA 5.54 ILA 63

P/S Multiple 0.7200 ILA 0.9600 ILA 1.20 ILA 58

P/B Multiple 2.18 ILA 2.90 ILA 3.63 ILA 55

EV/EBIT 2.52 ILA 3.73 ILA 4.93 ILA 65

EV/EBITDA 1.82 ILA 2.79 ILA 3.77 ILA 66

EV/Revenue — — 0.1500 ILA 50

Asset-Based

NCAV (Graham) 0.8100 ILA 1.08 ILA 1.61 ILA 54

Growth DCF

Growth DCF 2.59 ILA 6.55 ILA 13.07 ILA 73

Rev-Margin DCF 0.5200 ILA 1.43 ILA 2.73 ILA 68

Economic Profit

Residual Income 2.01 ILA 2.46 ILA 6.49 ILA 68

ROIC Compounder 2.97 ILA 4.91 ILA 6.61 ILA 71

Growth Earnings

Growth-Adj P/E 4.65 ILA 6.65 ILA 8.64 ILA 67

Widest divergence: Growth Earnings (6.65 ILA) versus Asset-Based (1.08 ILA). Highest evidence: EPV (74).

Notify me when NWMD reaches fair value

Put NWMD on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 28.2

P/S ratio 11.2 P/E × margin

EPS (TTM) 0.6100 ILA price ÷ EPS = P/E 28.2

Dividend yield 1.2% payout 34.9%

Net margin 39.6% FY2025

Return on equity 13.2% TTM

More key figures

Profitability

Return on assets (EBIT) 15.9% avg 5y

Operating margin 3.3% TTM

Growth

Revenue (TTM) 762M ILA TTM

Revenue growth (YoY) −42.6% 3y avg −6.4%

Balance sheet & cash flow

Free cash flow 305M ILA FY2025

Net debt 1.0B ILA FY2025 · ≈ 3.3 yrs of FCF

Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 57/100

Of which business quality 58 · Market factors (momentum, volatility) 51

Profitability 53

Margins and returns on capital today

Quality Growth 34

Are margins and returns improving?

Cashflow 75

Earnings quality: real cash, not paper profit

Fin. Strength 55

Balance sheet, leverage, solvency risk

Investment 44

Disciplined investing over empire-building

Low Volatility 79

Calm price path (market factor)

Momentum 38

Price trend over the last 3–12 months (market factor)

52W Momentum 42

Distance to the 52-week high (market factor)

Net Issuance 81

Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

NewMed Energy - Limited Partnership exploration, development, production, and marketing of natural gas, condensate, and oil in Israel, Jordan and Egypt.

Full company description

NewMed Energy - Limited Partnership exploration, development, production, and marketing of natural gas, condensate, and oil in Israel, Jordan and Egypt. The company holds interests in the Leviathan project, which covers an area of 500 square kilometer (km2) located to the west of the shores of Haifa; the Block 12 that covers an area of approximately 386 km2 located in Cyprus; and the Yam Tethys project, located to the west of the shores of Ashkelon. It also holds interests in the Boujdour Atlantique exploration license that covers an area of approximately 33,815 km2 located in the south of the Moroccan exclusive economic zone; and the Tanin and Karish leases covering an area of approximately 500km2 located to the west of the shores of Nahariya. The company serves independent power producers, marketing companies, and industrial customers, as well as exports natural gas to Jordan and in Egypt. The company was formerly known as Delek Drilling - Limited Partnership and changed its name to NewMed Energy - Limited Partnership in February 2022. NewMed Energy - Limited Partnership was incorporated in 1993 and is based in Herzliya, Israel.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

NewMed Energy - Limited Partnership reported revenue of $938M in FY2025 versus $883M in FY2021, a compound +1.5%/yr. Reported net income was $371M in FY2025, compounding −2.1%/yr from FY2021.

Growth Quality 40/100

Revenue growth is weak, negative or inconsistent.

Latest Revenue (FY 2025)

938M ILS

Latest YoY

−17.4%

Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

−6.4%

Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

+9.8%

Avg. revenue growth/yr (21Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

+18.4%

Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.

+1.5% (0.3 + 1.2)

Revenue +1.5%/yr

FY21 $883M

FY22 $1.1B

FY23 $935M

FY24 $1.1B

FY25 $938M

Net income −2.1%/yr

FY21 $405M

FY22 $470M

FY23 $434M

FY24 $525M

FY25 $371M

Character of growth · EPS growth decomposed (2014-2025) +10.8 % p.a.

Revenue per share +11.1 %

of which total revenue +16.7 % · buybacks/dilution −4.8 %

EBIT margin +2.3 %

Tax rate −2.9 %

Residual (interest, one-offs) +0.4 %

Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).

NWMD screens 60% overvalued. Compare with CNOOC Limited →

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

Share or link this analysis

𝕏 Post WhatsApp LinkedIn Reddit

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

NewMed Energy - Limited Partnership · Fair Value
10.77 ILA −60%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/NWMD" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">NewMed Energy - Limited Partnership · Fair Value</span><br><b style="font-size:20px">10.77 ILA</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−60%</span></span><span style="font-size:11px;color:#7BB290;font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "NewMed Energy - Limited Partnership Fair Value". https://www.fairvalue-calculator.com/stock/NWMD

Peer Group

Oil & Gas E&P · 296 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 57 · Top 25%

Fair Value upside −37% · Below median

Return on equity (TTM) 13% · Top 25%

Return on assets 5% · Above median

Net margin (TTM) 30% · Top 25%

Operating margin (TTM) 3% · Below median

Revenue growth −43% · Bottom 25%

Dividend yield (TTM) 1.2% · Bottom 25%

Debt / equity 0.74× · Higher than 75% of peers

Valuation Multiples vs Oil & Gas E&P median · lower = cheaper

P/E (TTM) 28.2× · Pricier than 75% of peers

P/B 3.39× · Pricier than 75% of peers

P/S (TTM) 8.41× · Pricier than 75% of peers

P/FCF 21.0× · Pricier than 75% of peers

EV/EBITDA 13.1× · Pricier than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

This stock

Sector peers

VALUE0 · sector 9

FUTURE0 · sector 7

PAST53 · sector 9

HEALTH63 · sector 87

DIVIDEND25 · sector 70

VALUE 0: the price sits above our fair-value range.

Insider activity: 45/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Oil & gas

Similar stocks

10 more Oil & Gas E&P stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).

Stock	Price	Fair Value	vs Fair Value
CNOOC Limited 600938	¥32.85	¥32.55	−1%
ConocoPhillips explores for, COP	$130.35	$90.15	−31%
Canadian Natural Resources Limited CNQ	C$69.03	C$44.78	−35%
EOG Resources, Inc EOG	$143.35	$132.20	−8%
Occidental Petroleum Corporation OXY	$59.17	$30.06	−49%
Diamondback Energy, Inc FANG	$200.52	$105.24	−48%
Devon Energy Corporation DVN	$47.35	$27.06	−43%
Woodside Energy Group WDS	A$32.55	A$20.71	−36%
EQT Corporation EQT	$54.57	$42.85	−21%
Texas Pacific Land Corporation TPL	$366.50	$77.26	−79%

Compare NewMed Energy - Limited Partnership with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Explore undervalued stocks

More undervalued Energy stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is NewMed Energy - Limited Partnership (NWMD) overvalued or undervalued?

As of Aug 20, 2026, our model estimates a fair value of 10.77 ILA versus a price of 17.19 ILA, about −37% upside (overvalued).

What is the fair value of NWMD?

Our model-based fair value for NewMed Energy - Limited Partnership is 10.77 ILA (as of Aug 20, 2026), built from audited fundamentals. The current price: 17.19 ILA.

What is the quality score of NWMD?

NewMed Energy - Limited Partnership has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the revenue of NewMed Energy - Limited Partnership (NWMD)?

NewMed Energy - Limited Partnership reported trailing-twelve-month revenue of about 762M ILS (latest available figure, as of Aug 20, 2026).

What is the net profit margin of NWMD?

The net profit margin of NewMed Energy - Limited Partnership is about 29.8%, meaning it keeps roughly 29.8% of revenue as net income. Based on the latest reported figures.

Does NewMed Energy - Limited Partnership pay a dividend?

NewMed Energy - Limited Partnership currently shows a dividend yield of about 1.24% relative to its recent price (as of Aug 20, 2026).

Free · no account needed

Watch NewMed Energy - Limited Partnership in the live analysis

One click puts NewMed Energy - Limited Partnership on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.